Mechanisms of p53-mediated apoptosis

Critical Reviews in Oncogenesis

Volumn 9, Issue 1, 1998, Pages 83-98

  Ding, Han Fei ^a,c   Fisher, David E ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Dana 630F ^*  (United States)

Author keywords

Caspases; Programmed cell death; Tumor suppressors; Tumor therapy; Tumorigenesis

Indexed keywords

FAS ANTIGEN; PROTEIN BAX; PROTEIN P53; PROTEINASE; SOMATOMEDIN BINDING PROTEIN 3; TUMOR NECROSIS FACTOR RECEPTOR;

AMINO ACID COMPOSITION; APOPTOSIS; CANCER THERAPY; CARCINOGENESIS; CELL TYPE; DNA DAMAGE; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE; PROTEIN DOMAIN; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0031783353     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v9.i1.60     Document Type: Review

References (173)

1. Agoff, S. N., J. Hou, D. I. H. Linzer, and B. Wu: Regulation of the human hsp70 promoter by p53. Science, 259:84-87 (1993).
2. Allday, M. J., G. J. Inman, D. H. Crawford, and P. J. Farrell: DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J., 14:4994-5005 (1995).
3. Alnemri, E. S., D. J. Livingston, D. W. Nicholson, G. Salvesen, N. A. Thornberry, W. W. Wong, and J. Yuan: Human ICE/CED-3 protease nomenclature. Cell, 87:171 (1996).
4. Antonsson, B., F. Conti, A. Ciavatta, S. Montessuit, S. Lewis, I. Martinou, L. Bernasconi, A. Bernard, J. J. Mermod, G. Mazzei, K. Maundrell, F. Gambale, R. Sadoul, and J. C. Martinou: Inhibition of Bax channel-forming activity by Bcl-2. Science, 277:370-372 (1997).
5. Attardi, L. D., S. W. Lowe, J. Brugarolas, and T. Jacks: Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J., 15:3693-3701 (1996).
6. Aurelio, O. N., J.-F. Cajot, M. L.-H. Hua, Z. Khwaja, and E. J. Stanbridge: Germ-line-derived hinge domain p53 mutants have lost apoptotic but not cell cycle arrest functions. Cancer Res., 58:2190-2195 (1998).
7. Avantaggiati, M. L., V. Ogryzko, K. Gardner, A. Giordano, A. S. Levine, and K. Kelly: Recruitment of p300/CBP in p53-dependent signal pathways. Cell, 89:1175-1184 (1997).
8. Bardeesy, N., J. B. Beckwith, and J. Pelletier: Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res., 55:215-219 (1995).
9. Bargonetti, J., J. J. Manfredi, X. Chen, D. R. Marshak, and C. Prives: Genes Dev., 7:2565-2574 (1993).
10. Bellamy, C. O.: p53 and apoptosis. Br. Med. Bull., 53:522-538 (1997).
11. Brady, H. J., G. S. Salomons, R. C. Bobeldijk, and A. J. Berns: T cells from baxα transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J., 15:1221-1230 (1996).
12. Buckbinder, L., R. Talbott, M. S. Velasco, I. Takenaka, B. Fana, B. R. Seizinger, and N. Kley: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature, 377:646-649 (1995).
13. Bursch, W., L. Kleine, and M. Tenniswood: The biochemistry of cell death by apoptosis. Biochem. Cell Biol., 68:1071-1074(1990).
14. Caelles, C., A. Helmberg, and M. Karin: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature, 370:220-223 (1994).
15. Canman, C. E., T. M. Gilmer, S. B. Coutts, and M. B. Kastan: Growth factor modulation of p53-mediated growth arrest vs. apoptosis. Genes Dev., 9:600-611 (1995).
16. Cao, Y., Q. Gao, D. Wazer, and V. Band: Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells. Cancer Res., 57:5584-5589 (1997).
17. Chandler, J. M., E. S. Alnemri, G. M. Cohen, and M. MacFarlane: Activation of CPP32 and Mch3 alpha in wild-type p53-induced apoptosis. Biochem. J., 322:19-23 (1997).
18. Chen, X., L. Ko, L. Jayaraman, and C. Prives: p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev., 10:2438-2451 (1996).
19. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science, 265:346-355 (1994).
20. Clarke, A. R., C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper, and A. H. Wyllie: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature, 362:849-852 (1993).
21. Clore, G. M., J. G. Omichinski, K. Sakaguchi, N. Zambrano, H. Sakamoto, E. Appella, and A. M. Gronengorn: High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science, 265:386-391 (1994).
22. Crook, T., N. J. Marston, E. A. Sara, and K. H. Vousden: Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell, 79:817-827 (1994).
23. Debbas, M. and E. White: Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev., 7:546-554 (1993).
24. Donehower, L. A.: The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol., 7:269-278 (1996).
25. El-Deiry, W. S., S. E. Kinzler, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein: Definition of a consensus binding site for p53. Nature Genet., 1:45-49 (1992).
26. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein: WAF1, a potential mediator of p53 tumor suppression. Cell, 75:817-825 (1993).
27. Eliyahu, D., D. Michalovitz, S. Eliyahu, O. Pinhasi-Kimhi, and M. Oren: Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. U.S.A., 86:8763-8767 (1989).
28. Ellis, R. E., J. Yuan, and H. R. Horvitz: Mechanisms and functions of cell death. Annu. Rev. Cell Biol., 7:663-698 (1991).
29. Fields, S. and S. K. Jang: Presence of a potent transcription activating sequence in the p53 protein. Science, 249:1046-1049 (1990).
30. Finlay, C. A., P. W. Hinds, and A. J. Levine: The p53 protooncogene can act as a suppressor of transformation. Cell, 57:1083-1093 (1989).
31. Fisher, D. E.: Apoptosis in cancer therapy: crossing the threshold. Cell, 78:539-542 (1994).
32. Franke, T. F., D. R. Kaplan, and L. C. Cantley: P13K: Downstream AKTion blocks apoptosis. Cell, 88:435-437 (1997).
33. Friesen, C., I. Herr, P. H. Drammer, and K.-M. Debatin: Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med, 2:574-577 (1996).
34. Fuchs, E. J., K. A. McKenna, and A. Bedi: p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32β. Cancer Res., 57:2550-2554 (1997).
35. Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay: A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol., 12:2866-2871 (1992).
36. Ginsberg, D., D. Michael-Michalovitz, D. Ginsberg, and M. Oren: Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. Mol. Cell. Biol., 11:582-585 (1991).
37. Gorina, S. and N. P. Pavletich: Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science, 274:1001-1005 (1996).
38. Gottlieb, T. and M. Oren: p53 in growth control and neoplasia. Biochim. Biophys. Acta, 1287:77-102 (1996).
39. Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A. J. Giaccia: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature, 379:88-91 (1996).
40. Greenhalf, W., C. Stephan, and B. Chaudhuri: Role of mitochondria and C-terminal membrane anchor of Bcl-2 in Bax induced growth arrest and mortality in Saccharomyces cerevisiae. FEBS Lett., 380:169-175 (1996).
41. Gu, W., X.-L. Shi, and R. G. Roeder: Synergistic activation of transcription by CBP and p53. Nature, 387:819-823 (1997).
42. Gu, Y., C. W. Turck, and D. O. Morgan: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature, 366:707-710 (1993).
43. Gura, T.: How TRAIL kills cancer cells, but not normal cells. Science, 277:768 (1997).
44. Halazonetis, T. D. and A. N. Kandil: Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J., 12:5057-5064 (1993).
45. Han, J., P. Sabbatini, D. Perez, L. Rao, D. Modha, and E. White: The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev., 10:461-477 (1996).
46. Hanada, M., C. Aime-Sempe, T. Sato, and J. C. Reed: Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J. Biol. Chem., 270:11962-11969(1995).
47. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75:805-816 (1993).
48. Harris, C. C. and M. Hollstein: Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329:1318-1327 (1993).
49. Hartwell, L. H. and M. B. Kastan: Cell cycle control and cancer. Science, 266:1821-1828 (1994).
50. Haupt, Y., S. Rowan, E. Shaulian, A. Kazaz, K. Vousden, and M. Oren: p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. Leukemia, 11(Suppl 3):337-339 (1997).
51. Haupt, Y., S. Rowan, E. Shaulian, K. H. Vousden, and M. Oren: Induction of apoptosis in HeLa cells by transactivation-deficient p53. Genes Dev., 9:2170-2183 (1995).
52. Hermeking, H. and D. Eick: Mediation of c-Myc-induced apoptosis by p53. Science, 265:2091-2093 (1994).
53. Hollstein, M., K. Rice, M. S. Greenblatt, T. Soussi, R. Fuchs, T. Sorlie, E. Hovig, B. Smith-Sorenson, R. Montesano, and C. C. Harris: Database of p53 gene somatic mutations in human tumors and cell lines. Nucl. Acids Res., 22:3551-3555 (1994).
54. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris: p53 mutations in human cancers. Science, 253:49-53 (1991).
55. Horikoshi, N. A., A. Usheva, J. Chen, A. J. Levine, R. Weinmann, and T. Shenk: Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol. Cell. Biol., 15:227-234 (1995).
56. Howes, K. A., N. Ransom, D. S. Papermaster, J. G. Lasudry, D. M. Albert, and J. J. Windle: Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev., 8:1300-1310 (1994).
57. Hueber, A.-O., M. Zornig, D. Lyon, T. Suda, S. Nagata, and G. Evan: Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science, 278:1305-1309(1997).
58. Hunter, J. J. and T. G. Parslow: A peptide sequence from bax that converts bcl-2 into an activator of apoptosis. J. Biol. Chem., 271:8521-8524 (1996).
59. Israeli, D., E. Tessler, Y. Haupt, A. Elkeles, S. Wilder, R. Amson, A. Telerman, and M. Oren: A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J., 16:4384-4392 (1997).
60. Iwabuchi, K., P. L. Bartel, B. Li, R. Marraccino, and S. Fields: Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. U.S.A., 91:6098-6102 (1994).
61. Jacks, T. and R. A. Weinberg: Cell-cycle control and its watchman. Nature, 381:643-644 (1996).
62. Jacobson, M. D., M. Weil, and M. C. Raff: Programmed cell death in animal development. Cell, 88:347-354 (1997).
63. Jeffrey, P. D., S. Gorina, and N. P. Pavletich: Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science, 267:1498-1502 (1995).
64. Jurgensmeier, J. M., S. Krajewski, R. C. Armstrong, G. M. Wilson, T. Oltersdorf, L. C. Fritz, J. C. Reed, and S. Ottilie: Bax- and Bak-induced cell death in the fission yeast Schizosaccharomyces pombe. Mol. Biol. Cell., 8:325-339 (1997).
65. Kastan, M.: On the TRAIL from p53 to apoptosis? Nature Genet., 17:130-131 (1997).
66. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig: Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51:6304-6311 (1991).
67. Kerr, J. F., A. H. Wyllie, and A. R. Currie: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 26:239-257 (1972).
68. Knudson, C. M. and S. J. Korsmeyer: Bcl-2 and Bax function independently to regulate cell death. Nature Genet., 16:358-363 (1997).
69. Knudson, C. M., K. S. Tung, W. G. Tourtellotte, G. A. Brown, and S. J. Korsmeyer: Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science, 270:96-99 (1995).
70. Ko, L. J. and C. Prives: p53: puzzle and paradigm. Genes Dev., 10:1054-1072 (1996).
71. Kroemer, G.: The protooncogene Bcl-2 and its role in regulating apoptosis. Nature Med., 3:614-620 (1997).
72. Kulic, G., A. Klippel, and M. J. Weber: Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphotidylinositol 3-kinase, and Akt. Mol. Cell. Biol., 17:1595-1606(1997).
73. Kussie, P. H., S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A. J. Levine, and N. P. Pavletich: Crystal structure of the MDM2 oncoprotein bound to the transactivation domain of the p53 tumor suppressor. Science, 274:948-953 (1996).
74. Lane, D. P.: p53, guardian of the genome. Nature, 358:15-16 (1992).
75. Lee, W., T. S. Harvey, Y. Yin, P. Yau, D. Litchfield, and C. H. Arrowsmith: Solution structure of the tetrameric minimum transforming domain of p53. Nature Struct. Biol., 1:877-890 (1994).
76. Levine, A. J.: p53, the cellular gatekeeper for growth and division. Cell, 88:323-331 (1997).
77. Li, P., D. Nijhawan, I. Budihardjo, S. M. Srinivasula, M. Ahmad, E. S. Alnemri, and X. Wang: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91:479-489 (1997).
78. Li, X. and P. Coffino: High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J. Virol., 70:4509-4516 (1996).
79. Lill, N. L., S. R. Grossman, D. Ginsberg, J. DeCaprio, and D. M. Livingston: Binding and modulation of p53 by P300/CBP coactivators. Nature, 387:823-827 (1997).
80. Liu, X. S., C. N. Kim, J. Yang, R. Jemmerson, and X. D. Wang: Induction of apoptotic program in cell-free extracts - requirement for dATP and cytochrome C. Cell, 86:147-157 (1996).
81. Lotem, J. and L. Sachs: Differential suppression by protease inhibitors and cytokines of apoptosis induced by wild-type p53 and cytotoxic agents. Proc. Natl. Acad. Sci. U.S.A., 93:12507-12512 (1996).
82. Lowe, S. W., S. Bodis, A. McClatchey, L. Remington, H. E. Ruley, D. E. Fisher, D. E. Housman, and T. Jacks: p53 status and the efficacy of cancer therapy in vivo. Science, 266:807-810 (1994).
83. Lowe, S. W., T. Jacks, D. E. Housman, and H. E. Ruley: Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. U.S.A., 91:2026-2030 (1994).
84. Lowe, S. W. and H. E. Ruley: Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev., 7:535-545 (1993).
85. Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74:957-967 (1993).
86. Lowe, S.W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362:847-849 (1993).
87. Lu, H. and A. J. Levine: Human TAF-31 is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. U.S.A., 92:5154-5158 (1995).
88. MacFarlane, M., M. Ahmad, S. M. Srinivasula, T. Fernandes-Alnemri, G. M. Cohen, and E. S. Alnemri: Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem., 272:25417-25420 (1997).
89. Mack, D. H., V. J., J. M. Pipas, and L. A. Laimins: Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature, 363:281-283 (1993).
90. Malkin, D., F. P. Li, L. C. Strong, J. F. Fraumeni, C. E. Nelson, D. H. Kim, J. Kassel, M. A. Gryka, F. Z. Bischoff, M. A. Tainsky, and S. H. Friend: Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250:1233-1238 (1990).
91. Maltzman, W. and L. Czyzyk: UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol., 4:1689-1694 (1984).
92. Manon, S., B. Chaudhuri, and M. Guerin: Release of cytochrome C and decrease of cytochrome C oxidase in Bax-expressing yeast cells, and prevention of these effects by coexpression of Bcl-xL. FEBS Lett., 415:29-32 (1997).
93. Matlashewski, G. J., S. Tuck, D. Pim, P. Lamb, J. Schneider, and L. V. Crawford: Primary structure polymorphism at amino acid residue 72 of human p53. Mol. Cell. Biol., 7:961-963 (1987).
94. 1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells. Mol. Cell, 1:327-336 (1998).
95. McCurrach, M. E., T. M. F. Connor, C. M. Knudson, S. J. Korsmeyer, and S. W, Lowe: bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. U.S.A., 94:2345-2349 (1997).
96. Mignotte, B. and J.-L. Vayssiere: Mitochondria and apoptosis. Eur. J. Biochem., 252:1-15 (1998).
97. Miwa, K., S. Miyamoto, H. Kato, T. Imamura, M. Nishida, Y. Yoshikawa, Y. Nagata, and N. Wake: The role of p53 inactivation in human cervical cell carcinoma development. Br. J. Cancer, 71:219-226 (1995).
98. Miyashita, T., S. Krajewski, M. Krajewska, H. G. Wang, H. K. Lin, D. A. Liebermann, B. Hoffman, and J. C. Reed: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9:1799-1805 (1994).
99. Miyashita, T. and J. C. Reed: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80:293-299 (1995).
100. Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69:1237-1245 (1992).
101. Morgenbesser, S. D., B. O. Williams, T. Jacks, and R. A. DePinho: p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens [see comments]. Nature, 371:72-74 (1994).
102. Muller, M., S. Strand, H. Hug, E. M. Heinemann, H. Walczak, W. J. Hofmann, W. Stremmel, P. H. Krammer, and P. R. Galle: Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest., 99:403-413 (1997).
103. Murphy, M., A. Hinman, and A. J. Levine: Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev., 10:2971-2980 (1996).
104. Nagata, S.: Apoptosis by death factor. Cell, 88:355-365 (1997).
105. Naumovski, L., and M. L. Cleary: The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol. Cell. Biol., 16:3884-3892 (1996).
106. Nicholson, D. W. and N. A. Thornberry: Caspases: killer proteases. Trends Biochem. Sci., 22:299-306 (1997).
107. Oliner, J. D., K. W. Kanzler, P. S. Meltzer, D. L. George, and B. Vogelstein: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358:80-83 (1992).
108. Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein: Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature, 362:857-860 (1993).
109. Oltvai, Z. N., C. L. Milliman, and S. J. Korsmeyer: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74:609-619 (1993).
110. Owen-Schaub, L. B., W. Zhang, J. C. Cusack, L. S. Angelo, S. M. Santee, T. Fujiwara, J. A. Roth, A. B. Deisseroth, W. W. Zhang, E. Kruzel et al.: Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol., 15:3032-3040 (1995).
111. Pan, G., J. Ni, Y.-F. Wei, G.-L. Yu, R. Gentz, and V. M. Dixit: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 277:815-818 (1997).
112. Pan, H. and A. E. Griep: Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev., 8:1285-1299 (1994).
113. Pavletich, N. P., K. A. Chambers, and C. O. Pabo: The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev., 7:2556-2564 (1993).
114. Peitenpol, J. A., T. Tokono, S. Thiagalingam, W. S. El-Deiry, K. W. Kinzler, and B. S. Vogelstein: Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. U.S.A., 91:1998-2002 (1994).
115. Pitti, R. M., S. A. Marsters, S. Ruppert, C. J. Donahue, A. Moore, and A. Ashkenazi: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 271:12687-12690 (1996).
116. Polyak, K., Y. Xia, J. L. Zweier, K. W. Kinzler, and B. Vogelstein: A model for p53-induced apoptosis. Nature, 389:300-305 (1997).
117. Reed, J. C.: Double identity for proteins of the Bcl-2 family. Nature, 387:773-776 (1997).
118. Reinke, V. and G. Lozano: The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene, 15:1527-1534 (1997).
119. Rosse, T., R. Olivier, L. Monney, M. Rager, S. Conus, I. Fellay, B. Jansen, and C. Borner: Bcl-2 prolongs cell survival after Bax-induced release of cytochrome C. Nature, 391:496-499 (1998).
120. Rowan, S., R. L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, and K. H. Vousden: Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J., 15:827-838 (1996).
121. Ruley, H. E.: pS3 and response to chemotherapy and radiotherapy. Important Adv. Oncol., 1996:37-56 (1996).
122. Ruppert, J. M. and B. Stillman: Analysis of a protein-binding domain of p53. Mol. Cell. Biol., 13:3811-3820 (1993).
123. Sabbatini, P., J. Lin, A. J. Levine, and E. White: Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev., 9:2184-2192 (1995).
124. Saenz Robles, M. T., H. Symonds, J. Chen, and T. Van Dyke: Induction versus progression of brain tumor development: differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen. Mol. Cell. Biol., 14:2686-2698 (1994).
125. Sakamuro, D., P. Sabbatini, E. White, and G. C. Prendergast: The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene, 15:887-898 (1997).
126. Salvesen, G. S. and V. M. Dixit: Caspases: intracellular signaling by proteolysis. Cell, 91:443-446 (1997).
127. Sato, T., M. Hanada, S. Bodrug, S. Irie, N. Iwama, L. H. Boise, C. B. Thompson, E. Golemis, L. Fong, H. G. Wang, et al.: Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system. Proc. Natl. Acad. Sci. U.S.A., 91:9238-9242 (1994).
128. Schlesinger, P. H., A. Gross, X. M. Yin, K. Yamamoto, M. Saito, G. Waksman, and S. J. Korsmeyer: Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc. Natl. Acad. Sci. U.S.A., 94:11357-11362 (1997).
129. Schmaltz, C., P. H. Hardenbergh, A. Wells, and D. E. Fisher: Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol. Cell. Biol., 18:2845-2854 (1998).
130. Scolnick, D. M., N. H. Chehab, E. S. Stavridi, M. C. Lien, L. Caruso, E. Moran, S. L. Berger, and T. D. Halazonetis: CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res., 57:3693-3696 (1997).
131. Screaton, G. R., J. Mongkolsapaya, X. N. Xu, A. E. Cowper, A. J. McMichael, and J. Bell: TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signals from TRAIL. Curr. Biol., 7:693-696 (1997).
132. Sedlak, T. W., Z. N. Oltvai, E. Yang, K. Wang, L. H. Boise, C. B. Thompson, and S. J. Korsmeyer: Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc. Natl. Acad. Sci. U.S.A., 92:7834-7838 (1995).
133. Selvakumaran, M., H. K. Lin, T. Miyashita, H. G. Wang, S. Krajewski, J. C. Reed, B. Huffman, and D. Liebermann: Immediate early up-regulation of bax expression by p53 but not TGF beta 1 : a paradigm for distinct apoptotic pathways. Oncogene, 9:1791-1798 (1994).
134. Seto, E., A. Usheva, G. P. Zambetti, et al.: Wild-type p53 binds to the TATA-binding protein and repressed transcription. Proc. Natl. Acad. Sci. U.S.A., 89:12028-12032 (1992).
135. Sheikh, M. S., T. F. Burns, Y. Huang, G. S. Wu, S. Amundson, K. S. Brooks, A. J. Fornace Jr., and W. S. El-Deiry: p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor a. Cancer Res., 58:1593-1598 (1998).
136. Sheridan, J. P., S. A. Marsters, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, A. D. Goddard, P. Godowski, and A. Ashkenazi: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 277:818-821 (1997).
137. Srivastava, S., Z. Zou, K. Pirollo, W. Blattner, and E. H. Chang: Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature, 348:747-749 (1990).
138. Storey, A., M. Thomas, A. Kalita, C. Harwood, D. Gardiol, F. Mantovani, J. Breuer, I. M. Leigh, G. Matlashewski, and L. Banks: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature, 393:229-234 (1998).
139. Subler, M. A., D. W. Martin, and S. Deb: Inhibition of viral and cellular promoters by human wild-type p53. J. Virol., 66:4757-4762 (1992).
140. Sun, X. F., O. Johannsson, S. Hakansson, G. Sellberg, B. Nordenskjold, H. Olsson, and A. Borg: A novel p53 germline alteration identified in a late onset breast cancer kindred. Oncogene, 13:407-411 (1996).
141. Susin, S. A., N. Zamzami, M. Castedo, T. Hirsch, P. Marchetti, A. Macho, E. Daugas, M. Geuskens, and G. Kroemer: Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J. Exp. Med., 184:1331-1341 (1996).
142. Symonds, H., L. Krall, L. Remington, R. M. Saenz, S. Lowe, T. Jacks, and T. Van Dyke: p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell, 78:703-711 (1994a).
143. Symonds, H., L. Krall, L. Remington, M. Saenz Robles, T. Jacks, and T. Van Dyke: p53-dependent apoptosis in vivo: impact of p53 inactivation on tumorigenesis. Cold Spring Harbor Symp. Quant. Biol., 59:247-257 (1994b).
144. Tamura, T., N. Aoyama, H. Saya, H. Haga, S. Futami, M. Miyamoto, T. Koh, T. Ariyasu, M. Tachi, M. Kasuga, et al.: Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene, 11:1939-1946 (1995).
145. Thompson, C. B.: Apoptosis in the pathogenesis and treatment of disease. Science, 267:1456-1462 (1995).
146. Thut, C. J., J. L. Chen, R. Klemin, and R. Tjian: p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science, 267:100-104 (1995).
147. Unger, T., J. A. Mietz, M. Scheffner, C. L. Yee, and P. M. Howley: Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol. Cell. Biol., 13:5186-5194 (1993).
148. Unger, T., M. M. Nau, S. Segal, and J. D. Minna: p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J., 11:1383-1390 (1992).
149. Wagner, A. J., J. M. Kokontis, and N. Hay: Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev., 8:2817-2830 (1994).
150. Walczak, H., M. A. Degli-Esposti, R. S. Johnson, P. J. Smolak, J. Y. Waugh, N. Boiani, M. S. Timour, M. J. Gerhart, K. A. Schooley, C. A. Smith, R. G. Goodwin, and C. T. Rauch: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J., 16:5386-5397 (1997).
151. Walker, K. K. and A. J. Levine: Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. U.S.A., 93:15335-15340 (1996).
152. Wang, X. W., K. Forrester, H. Yeh, M. A. Feitelson, J. R. Gu, and C. C. Harris: Hepatitis B virus χ protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. U.S.A., 91:2230-2234 (1994).
153. Wang, X. W., W. Vermeulen, J. D. Coursen, M. Gibson, S. E. Lupold, K. Forrester, G. W. Xu, L. Elmore, H. Yeh, J. Hoeijmakers, and C. C. Harris: The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev., 10:1219-1232 (1996).
154. Wang, X. W., H. Yeh, L. Schaeffer, R. Roy, V. Moncollin, J. M. Egly, Z. Wang, E. C. Friedberg, M. K. Evans, B. G. Taffe, V. A. Bohr, J. H. Hoeijmakers, K. Forrester, and C. C. Harris: p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet., 10:188-195 (1995).
155. Wang, Y., M. Reed, P. Wang, J. E. Stenger, G. Mayr, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer: p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev., 7:2575-2586 (1993).
156. Wiley, S. R., K. Schooley, P. J. Smolak, W. S. Din, C.-P. Huang, J. K. Nicholl, G. R. Sutherland, T. D. Smith, C. Rauch, C. A. Smith, and R. G. Goodwin: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3:673-682 (1995).
157. Wiman, K. G.: p53: emergency brake and target for cancer therapy. Exp. Cell Res., 237:14-18 (1997).
158. Wu, G. S., T. F. Burns, E. R. R. McDonald, W. Jiang, R. Meng, I. D. Krantz, G. Kao, D. D. Gan, J. Y. Zhou, R. Muschel, S. R. Hamilton, N. B. Spinner, S. Markowitz, G. Wu, and W. S. el-Deiry: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet., 17:141-143 (1997).
159. Xiang, J., D. T. Chao, and S. J. Korsmeyer: BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc. Natl. Acad. Sci. U.S.A., 93:14559-14563 (1996).
160. Xiao, H., A. Pearson, B. Coulombe, R. Truant, S. Zhang, J. L. Regier, S. J. Triezenberg, D. Reinberg, O. Flores, C. J. Ingles, and J. Greenblatt: Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol. Cell. Biol., 14:7013-7024 (1994).
161. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach: p21 is a universal inhibitor of cyclin kinases. Nature, 366:701-704 (1993).
162. Yang, E., J. Zha, J. Jockel, L. H. Boise, C. B. Thompson, and S. J. Korsmeyer: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell, 80:285-291 (1995).
163. Yang, X., H. Y. Chang, and D. Baltimore: Autoproteolytic activation of pro-caspases by oligomerization. Mol. Cell, 1:319-325 (1998).
164. Yew, P. R. and A. J. Berk: Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature, 357:82-85 (1992).
165. Yew, P. R., X. Liu, and A. J. Berk: Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev., 8:190-202 (1994).
166. Yin, C., C. M. Knudson, S. J. Korsmeyer, and T. Van Dyke: Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature, 385:637-640 (1997).
167. Yin, X. M., Z. N. Oltval, and S. J. Korsmeyer: BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature, 369:321-323 (1994).
168. Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature, 352:345-347 (1991).
169. Zha, H., C. Aime-Sempe, T. Sato, and J. C. Reed: Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J. Biol. Chem., 271:7440-7444 (1996).
170. Zha, H., H. A. Fisk, M. P. Yaffe, N. Mahajan, B. Herman, and J. C. Reed: Structure-function comparisons of the proapoptotic protein Bax in yeast and mammalian cells. Mol. Cell. Biol., 16:6494-6508 (1996).
171. Zha, H. and J. C. Reed: Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J. Biol. Chem., 272:31482-1488 (1997).
172. Zhan, Q., S. Fan, I. Bae, C. Guillouf, D. A. Liebermann, P. M. O'Connor, and A. J. Fornace, Jr.: Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene, 9:3743-3751 (1994).
173. Zou, H., W. J. Henzel, X. Liu, A. Lutschg, and X. Wang: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome C-dependent activation of caspase-3. Cell, 90:405-413 (1997).